Daily1d
GSK, Vesalius Therapeutics collaborate for novel treatments for Parkinson's disease
Cambridge: Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common ...
BioPharma Dive5d
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
FierceBiotech5d
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Vesalius Announces Multi-Target Strategic Alliance With GSK To Develop Breakthrough Treatments For People Afflicted With Parkinson's Disease
Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover and ...
Yahoo Finance5d
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson's Disease
Nov. 12, 2024 /PRNewswire/ -- Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic ...
Morningstar5d
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson's Disease
Morningstar brands and products Company Portfolio ...
Bloomberg L.P.5d
GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
BioWorld4d
Vesalius-GSK $650M pact: Targeting Parkinson’s root causes
More than two years since emerging from stealth, Vesalius Therapeutics Inc. signed its first major pharma deal with GSK plc. Worth up to $650 million and possibly more if an option is exercised, the ...